- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07941713
Respiratory Restriction Leaded by Conventional or Minimally Invasive Sugical Repair of Oesophageal Atresia in Children (RestriMIS2)
Assessment of Respiratory Restriction Caused by Chest Wall Abnormalities Following Conventional or Minimal Invasive Surgical Repair of Type III Esophageal Atresia in School Age Children
Children born with esophageal atresia need surgery shortly after birth. For many years, the standard operation was a thoracotomy, an opening in the chest that can sometimes lead to changes in the shape of the chest wall. Although these changes are visible on X rays, doctors still do not fully understand how much they affect breathing later in childhood. A newer, less invasive technique called thoracoscopy uses small incisions and appears to cause fewer chest deformities, but its impact on lung function has not yet been clearly established.
This study aims to compare the breathing capacity of children aged 6 to 9 who were operated on using either thoracotomy or thoracoscopy. The main question is whether one group is more likely to develop restrictive lung syndrome, a condition in which the lungs cannot expand normally. To answer this, the study relies on lung function tests and chest X rays performed during routine follow up visits.
Beyond this primary goal, the study also examines other possible breathing problems, the presence of chest wall abnormalities, and factors that might influence lung health, such as nutrition, physical activity, associated malformations, and overall quality of life.
A total of at least 360 children across France will participate. They are identified through national registries and invited during scheduled follow up consultations.
Studienübersicht
Status
Studientyp
Einschreibung (Geschätzt)
Kontakte und Standorte
Studienkontakt
- Name: Francoise SCHMITT, MD
- Telefonnummer: +33 2 41 35 42 90
- E-Mail: FrSchmitt@chu-angers.fr
Studieren Sie die Kontaktsicherung
- Name: Josue Rakotonjanahary
- Telefonnummer: +33 2 41 35 57 40
- E-Mail: JoRakotonjanahary@chu-angers.fr
Studienorte
-
-
-
Amiens, Frankreich, 80054
- CHU Amiens, Département de Pédiatrie, centre d'activité "chirurgie pédiatrique viscérale"
-
Kontakt:
- Philippe BUISSON, MD
- Telefonnummer: +33 3 22 08 75 60
- E-Mail: buisson.philippe@chu-amiens.fr
-
Hauptermittler:
- Philippe BUISSON, MD
-
Angers, Frankreich, 49933
- CHU Angers, Service Urgences, Médecine, Psychiatrie et Chirurgie Pédiatriques
-
Kontakt:
- Francoise SCHMITT, MD
- Telefonnummer: 2 41 35 42 90
- E-Mail: FrSchmitt@chu-angers.fr
-
Kontakt:
- E-Mail: JoRakotonjanahary@chu-angers.fr
-
Hauptermittler:
- francoise SCHMITT, MD
-
Clermont-Ferrand, Frankreich, 63003
- CHU Clermont-Ferrand, Service de pédiatrie générale et multidisciplinaire
-
Kontakt:
- Carole Egron, MD
- Telefonnummer: +33 4 73 75 00 24
- E-Mail: cegron@chu-clermontferrand.fr
-
Hauptermittler:
- Carole EGRON, MD
-
Dijon, Frankreich, 21000
- CHU Dijon, Service de chirurgie pédiatrique
-
Kontakt:
- Michel FRANCOIS, MD
- Telefonnummer: +33 3 80 28 14 35
- E-Mail: michel.françois@chu-dijon.fr
-
Hauptermittler:
- Michel FRANCOIS, MD
-
Grenoble, Frankreich, 38700
- CHU Grenoble, Service de chirurgie pédiatrique
-
Kontakt:
- Pierre-Yves RABATTU, MD
- Telefonnummer: +33 4 76 76 59 00
- E-Mail: pyrabattu@chu-grenoble.fr
-
Hauptermittler:
- Pierre-Yves RABATTU, MD
-
Le Kremlin-Bicêtre, Frankreich, 94275
- Hôpital Bicêtre, AP-HP, Chirurgie Viscérale Pédiatrique
-
Kontakt:
- Khadidja KHADIR, MD
- Telefonnummer: +33 1 45 21 21 21
- E-Mail: khadidja.khadir@aphp.fr
-
Hauptermittler:
- Khadidja KHADIR, MD
-
Lyon, Frankreich, 69677
- Hospices Civils de Lyon, Service d'Hepato-Gastroentérologie et Nutrition Pédiatrique
-
Kontakt:
- Nicolas CARON, MD
- Telefonnummer: +33 4 72 35 70 50
- E-Mail: nicolas.caron@chu-lyon.fr
-
Hauptermittler:
- Nicolas CARON, MD
-
Nantes, Frankreich, 44093
- CHU Nantes, Hôpital Mère-Enfant, Service de Chirurgie Infantile
-
Kontakt:
- Audrey GUINOT, MD
- Telefonnummer: +33 2 40 08 35 85
- E-Mail: audrey.guinot@chu-nantes.fr
-
Hauptermittler:
- Audrey GUINOT, MD
-
Paris, Frankreich, 75015
- Hôpital Necker Enfants Malades, AP-HP, Service de Pneumologie et Allergologie Pédiatriques
-
Kontakt:
- Rola ABOU TAAM, MD
- Telefonnummer: +33 1 44 38 15 65
- E-Mail: rola.aboutaam@aphp.fr
-
Hauptermittler:
- Rola ABOU TAAM, MD
-
Strasbourg, Frankreich, 67098
- CHU Strasbourg, Service de chirurgie pédiatrique
-
Kontakt:
- Isabelle TALON, MD
- Telefonnummer: +33 3 88 12 73 17
- E-Mail: isabelle.talon@chru-strasbourg.fr
-
Toulouse, Frankreich, 31059
- CHU Toulouse, Service de Chirurgie Viscérale Pédiatrique
-
Kontakt:
- Aurélie LE MANDAT, MD
- Telefonnummer: +33 5 34 55 85 44
- E-Mail: lemandat.a@chu-toulouse.fr
-
Hauptermittler:
- Aurelie LE MANDAT, MD
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Eligible patients in both groups are mainly identified through the national esophageal atresia registry (RENATO, CRACMO, CHU Lille).
Beschreibung
For thoracoscopy group:
Inclusion Criteria:
- Child operated on by thoracoscopy for type 3 AO (excluding long gap) according to Ladd's classification
- Child aged 6 to 10 years old
- Consent from parents (or legal guardians) and the child's agreement to participate in the study
Exclusion Criteria:
- Heart or lung malformation diagnosed at birth and requiring surgery
- Conversion from thoracoscopy to thoracotomy during the procedure
- Child who has had more than one thoracic surgery (reoperation for AO, other reasons for thoracic surgery including heart surgery)
- For Thoracotomy group*:
Inclusion Criteria :
--Child operated on by thoracotomy for type 3 AO (excluding long gap) according to the Ladd classification
- Child aged 6 to 10 years old
- Consent from parents (or legal guardians) and the child's agreement to participate in the study
Exclusion Criteria:
- Heart or lung malformation diagnosed at birth and requiring surgery
- Child who has had more than one thoracic surgery (reoperation for AO, other reason for thoracic surgery including heart surgery)
- Child operated on for type 3 AO via thoracotomy (excluding long gap) according to Ladd's classification
For each patient who underwent thoracoscopic surgery included in the study, two patients who had thoracotomy, matched according to known or suspected confounding factors for restrictive syndromes from the RestriMIS1 (NCT04136795) study**, will be included.
*It's possible that some children had multiple consecutive surgeries. In those cases, if one of the procedures was a thoracotomy, the children will be classified in the thoracotomy group (the more major surgery).
**Prematurity, birth weight, presence of tracheomalacia, and GERD during the neonatal period (clinically and/or on additional tests)
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: COHORT
- Zeitperspektiven: PROSPECTIVE
Kohorten und Interventionen
Gruppe / Kohorte |
|---|
|
thoracoscopy group
minimally invasive surgical approach |
|
thoracotomy arm
conventionnal surgical approach |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
to assess the presence of a restrictive lung syndrome in patients with type 3 esophageal atresia (EA) depending on the type of surgical approach used (conventional or minimally invasive).
Zeitfenster: Lung function tests can be done up to 2 years after the multidisciplinary consultation (Visit 0)
|
Rate of restrictive syndrome according to the type of surgical approach (conventional or minimally invasive), defined by spirometry data: FEV1/FVC > -1.64 Z-score and FVC < -1.64 Z-score, according to the ATS/ERS-GLI (American Thoracic Society & European Respiratory Society - Global Lung Initiative) recommendations published in 2012 (Quanjer) and reviewed en 2022. |
Lung function tests can be done up to 2 years after the multidisciplinary consultation (Visit 0)
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
to evaluate the importance of restrictive syndrome
Zeitfenster: importance of restrictive syndrome can be evaluated up to 2 years after the multidisciplinary consultation (visit 0)
|
The importance of restrictive syndrome is classified into 3 levels: mild restrictive syndrome [-1.64 > z-score ≥ -2.5], moderate [-2.5 > z-score ≥ -4.0], or severe [-4.0 > z-score]). |
importance of restrictive syndrome can be evaluated up to 2 years after the multidisciplinary consultation (visit 0)
|
|
Looking for other respiratory parameters
Zeitfenster: the link between chest skeletal abnormalities found on chest X-rays and lung impact can be evaluated up to 2 years after the multidisciplinary consultation
|
Other respiratory changes are examined by measuring other respiratory parameters (forced vital capacity, FEF 25-75, Tiffeneau ratio, reversibility), which help highlight obstructive or mixed syndromes (FEV1/FVC < -1.64 and FVC < -1.64 z-score) when present |
the link between chest skeletal abnormalities found on chest X-rays and lung impact can be evaluated up to 2 years after the multidisciplinary consultation
|
|
to assess the link between chest skeletal abnormalities found on chest X-rays and lung impact
Zeitfenster: until spirometry is completed, within a maximum period of 2 years
|
The following factors are considered when estimating the risk of association with or without a restrictive syndrome (history data like prematurity or types of malformations associated with AO III, surgical and medical care data in the neonatal period and childhood, growth data at one year and at 6-10 years), lung care, physical activity, the PedsQL score (for children aged 6 to 10), and responses to the EA-QoL questionnaire (for children aged 8 to 10). |
until spirometry is completed, within a maximum period of 2 years
|
|
rate of postoperative complications and any necessary reoperations
Zeitfenster: up to 2 years after the multidisciplinary consultation
|
The rate of postoperative complications is assessed by type of surgery as well as any necessary follow-up surgeries. |
up to 2 years after the multidisciplinary consultation
|
|
Respiratory-related quality of life during childhood
Zeitfenster: up to 2 years after the multidisciplinary consultation
|
It will be estimated through both need for lung care, physical activity, PedsQL score (for children aged 6 to 10), and EA-QoL questionnaire (for children aged 8 to 10). |
up to 2 years after the multidisciplinary consultation
|
|
to assess the existence of a cause-and-effect link between the restrictive syndrome and the surgical technique used
Zeitfenster: through study completion, within a maximum of 24 months
|
The acceptability of the existence of a causal link is assessed using sensitivity analysis, which estimates how robust the results are while taking into account missing data and different clinical scenarios (including a per-protocol analysis in addition to the intention-to-treat analysis). |
through study completion, within a maximum of 24 months
|
|
to assess the mortality rate
Zeitfenster: through study completion, an average 7 years
|
The death rate for each surgery group will be described based on the follow-up in the study, that is, the date of the surgery (combined data for all patients in the registry). |
through study completion, an average 7 years
|
|
Looking for lung volumes variations
Zeitfenster: the link between chest skeletal abnormalities found on chest X-rays and MRI lung volumes can be evaluated up to 2 years after the multidisciplinary consultation
|
Lung volume variations will be measured by dynamic respiratory MRI data |
the link between chest skeletal abnormalities found on chest X-rays and MRI lung volumes can be evaluated up to 2 years after the multidisciplinary consultation
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 49RC25_0432
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .